ResMed Statistics
Total Valuation
ResMed has a market cap or net worth of 35.87 billion. The enterprise value is 35.77 billion.
| Market Cap | 35.87B |
| Enterprise Value | 35.77B |
Important Dates
The next estimated earnings date is Friday, August 1, 2025.
| Earnings Date | Aug 1, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | n/a |
| Shares Outstanding | n/a |
| Shares Change (YoY) | -0.07% |
| Shares Change (QoQ) | -0.18% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 145.62M |
Valuation Ratios
The trailing PE ratio is 27.32 and the forward PE ratio is 23.98.
| PE Ratio | 27.32 |
| Forward PE | 23.98 |
| PS Ratio | 7.14 |
| PB Ratio | 6.47 |
| P/TBV Ratio | 15.82 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 19.72, with an EV/FCF ratio of 22.80.
| EV / Earnings | 27.24 |
| EV / Sales | 7.12 |
| EV / EBITDA | 19.72 |
| EV / EBIT | 22.14 |
| EV / FCF | 22.80 |
Financial Position
The company has a current ratio of 3.41, with a Debt / Equity ratio of 0.15.
| Current Ratio | 3.41 |
| Quick Ratio | 2.06 |
| Debt / Equity | 0.15 |
| Debt / EBITDA | 0.46 |
| Debt / FCF | 0.54 |
| Interest Coverage | 139.28 |
Financial Efficiency
Return on equity (ROE) is 25.81% and return on invested capital (ROIC) is 16.54%.
| Return on Equity (ROE) | 25.81% |
| Return on Assets (ROA) | 14.01% |
| Return on Invested Capital (ROIC) | 16.54% |
| Return on Capital Employed (ROCE) | 24.33% |
| Revenue Per Employee | 503,159 |
| Profits Per Employee | 131,589 |
| Employee Count | 9,980 |
| Asset Turnover | 0.70 |
| Inventory Turnover | 2.09 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +31.92% in the last 52 weeks. The beta is 0.78, so ResMed's price volatility has been lower than the market average.
| Beta (5Y) | 0.78 |
| 52-Week Price Change | +31.92% |
| 50-Day Moving Average | 26.68 |
| 200-Day Moving Average | 21.88 |
| Relative Strength Index (RSI) | 55.45 |
| Average Volume (20 Days) | 45 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 10.02 |
Income Statement
In the last 12 months, ResMed had revenue of 5.02 billion and earned 1.31 billion in profits. Earnings per share was 8.91.
| Revenue | 5.02B |
| Gross Profit | 2.98B |
| Operating Income | 1.61B |
| Pretax Income | 1.58B |
| Net Income | 1.31B |
| EBITDA | 1.76B |
| EBIT | 1.61B |
| Earnings Per Share (EPS) | 8.91 |
Balance Sheet
The company has 944.84 million in cash and 839.77 million in debt, giving a net cash position of 105.07 million.
| Cash & Cash Equivalents | 944.84M |
| Total Debt | 839.77M |
| Net Cash | 105.07M |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 5.55B |
| Book Value Per Share | 37.83 |
| Working Capital | 2.27B |
Cash Flow
In the last 12 months, operating cash flow was 1.65 billion and capital expenditures -84.16 million, giving a free cash flow of 1.57 billion.
| Operating Cash Flow | 1.65B |
| Capital Expenditures | -84.16M |
| Free Cash Flow | 1.57B |
| FCF Per Share | n/a |
Margins
Gross margin is 59.37%, with operating and profit margins of 32.10% and 26.15%.
| Gross Margin | 59.37% |
| Operating Margin | 32.10% |
| Pretax Margin | 31.41% |
| Profit Margin | 26.15% |
| EBITDA Margin | 35.14% |
| EBIT Margin | 32.10% |
| FCF Margin | 31.24% |
Dividends & Yields
ResMed does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | 23.14% |
| Buyback Yield | 0.07% |
| Shareholder Yield | 0.07% |
| Earnings Yield | 3.66% |
| FCF Yield | 4.37% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
ResMed has an Altman Z-Score of 12.61.
| Altman Z-Score | 12.61 |
| Piotroski F-Score | n/a |